Syneos Health Past Earnings Performance
Past criteria checks 1/6
Syneos Health has been growing earnings at an average annual rate of 34.5%, while the Life Sciences industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 6.4% per year. Syneos Health's return on equity is 2%, and it has net margins of 1.3%.
Key information
34.5%
Earnings growth rate
34.8%
EPS growth rate
Life Sciences Industry Growth | 26.8% |
Revenue growth rate | 6.4% |
Return on equity | 2.0% |
Net Margin | 1.3% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Syneos Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 5,419 | 71 | 612 | 0 |
31 Mar 23 | 5,414 | 148 | 569 | 0 |
31 Dec 22 | 5,393 | 266 | 547 | 0 |
30 Sep 22 | 5,407 | 287 | 559 | 0 |
30 Jun 22 | 5,419 | 278 | 568 | 0 |
31 Mar 22 | 5,340 | 242 | 574 | 0 |
31 Dec 21 | 5,213 | 235 | 571 | 0 |
30 Sep 21 | 4,980 | 251 | 542 | 0 |
30 Jun 21 | 4,730 | 236 | 521 | 0 |
31 Mar 21 | 4,461 | 198 | 484 | 0 |
31 Dec 20 | 4,416 | 193 | 473 | 0 |
30 Sep 20 | 4,489 | 192 | 464 | 0 |
30 Jun 20 | 4,567 | 187 | 456 | 0 |
31 Mar 20 | 4,720 | 195 | 459 | 0 |
31 Dec 19 | 4,676 | 131 | 508 | 0 |
30 Sep 19 | 4,608 | 86 | 444 | 0 |
30 Jun 19 | 4,546 | 17 | 431 | 0 |
31 Mar 19 | 4,452 | 19 | 420 | 0 |
31 Dec 18 | 4,390 | 24 | 406 | 0 |
30 Sep 18 | 3,995 | -36 | 434 | 0 |
30 Jun 18 | 3,472 | -174 | 426 | 0 |
31 Mar 18 | 2,658 | -184 | 368 | 0 |
31 Dec 17 | 1,853 | -138 | 314 | 0 |
30 Sep 17 | 1,365 | -86 | 221 | 0 |
30 Jun 17 | 1,033 | 89 | 174 | 0 |
31 Mar 17 | 1,033 | 116 | 174 | 0 |
31 Dec 16 | 1,030 | 113 | 172 | 0 |
30 Sep 16 | 1,009 | 106 | 171 | 0 |
30 Jun 16 | 984 | 116 | 170 | 0 |
31 Mar 16 | 952 | 109 | 164 | 0 |
31 Dec 15 | 915 | 117 | 157 | 0 |
30 Sep 15 | 887 | 33 | 154 | 0 |
30 Jun 15 | 860 | 8 | 152 | 0 |
31 Mar 15 | 837 | 0 | 149 | 0 |
31 Dec 14 | 810 | -27 | 145 | 0 |
30 Sep 14 | 770 | 13 | 139 | 0 |
30 Jun 14 | 732 | -1 | 128 | 0 |
31 Mar 14 | 687 | -27 | 123 | 0 |
31 Dec 13 | 652 | -42 | 118 | 0 |
31 Dec 12 | 579 | -60 | 109 | 0 |
Quality Earnings: 8IN has a large one-off loss of $132.0M impacting its last 12 months of financial results to 30th June, 2023.
Growing Profit Margin: 8IN's current net profit margins (1.3%) are lower than last year (5.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8IN has become profitable over the past 5 years, growing earnings by 34.5% per year.
Accelerating Growth: 8IN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 8IN had negative earnings growth (-74.4%) over the past year, making it difficult to compare to the Life Sciences industry average (12.2%).
Return on Equity
High ROE: 8IN's Return on Equity (2%) is considered low.